From a similar perspective, Zhang et al. developed iRGD-conjugated CSHNs containing paclitaxel and a P-glycoprotein inhibitor -tetradine -to overcome multidrug resistance of tumours and enhance anticancer activity based on a synergistic approach against ovarian cancer . In this way, P-glycoprotein (P-gp) should be inhibited and multidrug resistance (MDR) should be overcome simultaneously. For this reason, the drug development system needs to be studied in detail. For this reason, the release rate of paclitaxel covalently conjugated to the polymeric PLGA core with a redox-sensitive disulfide bond is controlled, while tetradine was loaded into the polymeric core by the nanoprecipitation method. To increase the penetration ability of these double-loaded particles, their surface is again derivatized with a cell-penetrating peptide (iRGD in this case). Cell culture studies have shown that these combined drug delivery systems, containing an anticancer drug and a P-gp inhibitor, can together increase apoptosis of A2780/PTX cells and effectively overcome tumour drug resistance. This demonstrated that tetradine was released rapidly before paclitaxel and inhibited P-gp, while paclitaxel was released from the nanoparticles in a controlled manner. These results reveal that it is possible to achieve many therapeutic effects simultaneously by controlling the encapsulation process (and thus the release of the drug).